The US has cleared two covid-19 treatment pills first, and now comes other obstacles – decide who to get which one.
Molnupiravir Merck & Co. Authorities on Thursday by feeding food and drugs to be used in adults with high risk of severe cases that have no choice of care, although not recommended for pregnant women. However, the US will soon have 3 million courses available.

Meanwhile, Paxlovid Pfizer Inc. – Authorized earlier this week – showed clinical clinical test data that was stronger with President Joe Biden called pill as a “promising new treatment”. This will be available in a limited amount at first when Pfizer grinds through a manufacturing process for months.

Regulators signal they prefer Pfizer pills, which they have purchased more, but the US will have earlier on Merck pills, which regulators say better than no treatment. The next few weeks will see the country and the hash doctor who gets what.

The US will have hundreds of thousands of Merck courses immediately available, and 3 million at the end of January, or about the entire order, the government said. On the contrary, the US is expected to receive only 265,000 pfizer care courses at the end of January, up to 2 million per month in the spring and a total of 10 million in July. Initial shipping is only 65,000 courses, or around 3,180 for New York, for example.

Biden, talking to ABC News this week, acknowledged that the supply of PFIZER “would not be enough to get to all hospitals” at first but the government had ordered everything that could be done by Pfizer so far. “If people get shots, they get two shots and booster, they will not be in a position where they really need such pills,” he said.

The National Institution of the Health Guidelines Committee compiled a list of recommendations on how to allocate care, and the US government will distribute pills through channels that have been used for existing care – send them based on per-capita to state temporarily. Also send it to other entities, such as the public health center that meets the requirements, in an effort to minimize race gaps in availability.

But in the end it will reach the doctor to prescribe who gets Paxlovid at first and who gets an alternative to Merck.

“It will almost certainly be a doctor to write a prescription for someone who is in the first three days of the famous Covid symptoms, and is in a high-risk group to get it,” Anthony Fauci, Head of Biden’s medical adviser, said on Wednesday, said Wednesday, said Wednesday, Merck authorization. “This, obviously, a very difficult situation when you have limited supplies.”

Celine Gounder, a doctor who suggested the Biden transition team in Covid, said he believed the Merck pill had a “limited utility” and was worried about the lack of Pfizer. Even if the doctor prioritizes the use of paxlovid for seniors with underlying medical conditions, for example, “I am very worried about the lack of inventory. It’s hardly enough to meet needs,” he said.

Recommendations will also consider whether other treatments may be more appropriate, said Fauci, such as Merck, remediesivir or monoclonal antibodies. Recommendations will target the highest risk, which “is for the purpose you want, because we have limited supplies, that we will have a priority about what the best approach,” Fauci said.

Molnupiravir, was developed with Ridgeback Biotheapeutics LP partners, authorized by the FDA Thursday morning to be used in several cases. Merck will be used among adults, and not among pregnant women, and for people “who are for whom the Covid-19 alternative treatment options passed by the FDA are inaccessible,” said the agency, a narrower feasibility window than specified for Pfizer.